US Stock MarketDetailed Quotes

BY Byline Bancorp

Watchlist
  • 27.860
  • +0.140+0.51%
Close Jan 8 16:00 ET
  • 28.090
  • +0.230+0.83%
Pre 04:31 ET
1.24BMarket Cap10.09P/E (TTM)

Byline Bancorp Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Byline Bancorp Q4 2024 Estimates Date

Currency：USDJan 23, 2025

Estimate YoY
Revenue
100.37M
-0.41%
EPS
0.61
-10.78%
Analyst Rating
Buy

Dec 31, 2024

Byline Bancorp Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 99.205M--
Jan 23, 20252024/Q4-- / 100.374M--
Oct 24, 20242024/Q3101.840M / 101.082M--
Jul 25, 20242024/Q299.370M / 99.207M--
Apr 25, 20242024/Q1101.014M / 98.059M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 99.205M--
Jan 23, 20252024/Q4-- / 100.374M--
Oct 24, 20242024/Q3101.840M / 101.082M--
Jul 25, 20242024/Q299.370M / 99.207M--
Apr 25, 20242024/Q1101.014M / 98.059M--

Unlock Free Earnings Estimates

Byline Bancorp Earnings Reports

  • Byline Bancorp | 10-Q: Q3 2024 Earnings Report

    Nov 1, 2024 16:09 ET

  • Byline Bancorp | 8-K: Byline Bancorp, Inc. Reports Third Quarter 2024 Financial Results

    Oct 24, 2024 16:19 ET

  • Byline Bancorp | 10-Q: Q2 2024 Earnings Report

    Aug 5, 2024 16:53 ET

  • Byline Bancorp | 8-K: Byline Bancorp, Inc. Reports Second Quarter 2024 Financial Results

    Jul 25, 2024 16:19 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Collegium Pharmaceutical
    COLL
    +14.41%
    eBay
    EBAY
    +9.86%
    Halozyme Therapeutics
    HALO
    +5.02%
    SilverCrest Metals
    SILV
    +4.63%
    Workday
    WDAY
    +2.01%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Dec 31, 2024

    Buy

    • Buy

      50.00%

    • Hold

      50.00%

    • Sell

      0.00%

    Price Target

    No Data